My ePortfolio Register   

SABCS 2016 /
TCHP with/out oestrogen for HR/HER positive breast cancer

6th - 10th Dec 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 08.12.16
Views: 806

Dr Mothaffar Rimawi - Baylor College of Medicine, Houston, USA

Dr Rimawi presents data at SABCS 2016 about the influence of added oestrogen deprivation to neo-adjuvant chemotherapy to with HR/HER2 positive breast cancer patients.

Overall, he describes additional therapy as not producing clinically significant results, which could be attributed to the chemotherapy regimen 'blunting' the clinical benefit of anti-oestrogens.

For more from this trial, Dr Rimawi spoke with ecancer, with a video interview coming soon.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence